131 related articles for article (PubMed ID: 29152093)
1. The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China.
Xing P; Zhu Y; Shan L; Chen S; Hao X; Li J
Oncotarget; 2017 Oct; 8(50):87442-87454. PubMed ID: 29152093
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel for non-small cell lung cancer patients who have failed at least two prior systemic treatments.
Duan J; Hao Y; Wan R; Yu S; Bai H; An T; Zhao J; Wang Z; Zhuo M; Wang J
Thorac Cancer; 2017 May; 8(3):138-146. PubMed ID: 28304139
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle albumin-bound paclitaxel in elder patients with advanced squamous non-small-cell lung cancer: A retrospective study.
Liu Y; Dong Y; Zhu H; Jing W; Guo H; Yu J
Cancer Med; 2020 Feb; 9(4):1365-1373. PubMed ID: 31876976
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer.
Anzai M; Morikawa M; Okuno T; Umeda Y; Demura Y; Sonoda T; Yamaguchi M; Kanno K; Shiozaki K; Ameshima S; Akai M; Ishizuka T
Medicine (Baltimore); 2017 Dec; 96(51):e9320. PubMed ID: 29390506
[TBL] [Abstract][Full Text] [Related]
5. A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma.
Jin F; Zhu H; Shi F; Kong L; Yu J
Clin Interv Aging; 2016; 11():167-73. PubMed ID: 26929611
[TBL] [Abstract][Full Text] [Related]
6. A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer.
Kato Y; Okuma Y; Watanabe K; Yomota M; Kawai S; Hosomi Y; Okamura T
Cancer Chemother Pharmacol; 2019 Aug; 84(2):351-358. PubMed ID: 30993397
[TBL] [Abstract][Full Text] [Related]
7. Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer.
Kotake M; Kuwako T; Imai H; Tomizawa Y; Kaira K; Yoshii A; Ochiai M; Miura Y; Osaki T; Sakurai R; Takei K; Minato K; Saito R
Chemotherapy; 2020; 65(1-2):21-28. PubMed ID: 32674095
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer.
Gong W; Sun P; Mu Z; Liu J; Yu C; Liu A
Anticancer Res; 2017 Aug; 37(8):4687-4691. PubMed ID: 28739772
[TBL] [Abstract][Full Text] [Related]
9. Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.
Fabi A; Giannarelli D; Malaguti P; Ferretti G; Vari S; Papaldo P; Nisticò C; Caterino M; De Vita R; Mottolese M; Iacorossi L; Cognetti F
Drug Des Devel Ther; 2015; 9():6177-83. PubMed ID: 26640370
[TBL] [Abstract][Full Text] [Related]
10. Efficiency and toxicity of nab-paclitaxel and camrelizumab in the second or above line treatment of advanced non-small cell lung cancer: a retrospective cohort study.
Yin C; Zou GR; He Y; Li J; Yan HW; Su Z; Cao XL; Li XB
J Thorac Dis; 2023 Apr; 15(4):1838-1847. PubMed ID: 37197501
[TBL] [Abstract][Full Text] [Related]
11. Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma.
Wang HY; Yao ZH; Tang H; Zhao Y; Zhang XS; Yao SN; Yang SJ; Liu YY
Onco Targets Ther; 2016; 9():5663-5669. PubMed ID: 27713635
[TBL] [Abstract][Full Text] [Related]
12. Investigating the relationship between secreted protein acidic and rich in cysteine expression level and therapeutic efficacy of nab-paclitaxel: a meta-analysis.
Zhou X; Zhang L; Qierang C; Huang M; Yang X; Li L; Jiang J
Transl Cancer Res; 2021 Feb; 10(2):876-885. PubMed ID: 35116417
[TBL] [Abstract][Full Text] [Related]
13. Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimen.
Hao X; Zhu Y; Mu Y; Wang S; Li J; Xing P
J Cancer; 2020; 11(21):6421-6428. PubMed ID: 33033525
[No Abstract] [Full Text] [Related]
14. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
[TBL] [Abstract][Full Text] [Related]
15. Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent.
Saxena A; Schneider BJ; Christos PJ; Audibert LF; Cagney JM; Scheff RJ
Med Oncol; 2016 Feb; 33(2):13. PubMed ID: 26749586
[TBL] [Abstract][Full Text] [Related]
16. Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer.
Shao H; Tang H; Salavaggione OE; Yu C; Hylander B; Tan W; Repasky E; Adjei AA; Dy GK
J Thorac Oncol; 2011 Jun; 6(6):998-1005. PubMed ID: 21532503
[TBL] [Abstract][Full Text] [Related]
17. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
Socinski MA; Bondarenko I; Karaseva NA; Makhson AM; Vynnychenko I; Okamoto I; Hon JK; Hirsh V; Bhar P; Zhang H; Iglesias JL; Renschler MF
J Clin Oncol; 2012 Jun; 30(17):2055-62. PubMed ID: 22547591
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Nanoparticle Albumin-Bound Paclitaxel (nab-PTX) Monotherapy Can Be Improved after Treatment with Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer: Long-Term Follow-Up and Updated Analysis of Two Previous Prospective Clinical Studies.
Nakashima K; Umeda Y; Demura Y; Sonoda T; Tada T; Yamaguchi M; Anzai M; Kadowaki M; Oi M; Honjo C; Mitsui M; Waseda Y; Ishizuka T
Oncology; 2024 Jan; ():1-11. PubMed ID: 38290482
[TBL] [Abstract][Full Text] [Related]
19. Potentially Overestimated Efficacy of Nanoparticle Albumin-bound Paclitaxel compared with Solvent-based Paclitaxel in Breast Cancer: A Systemic Review and Meta-analysis.
Li BX; Chen XJ; Ding TJ; Liu YH; Ma TT; Zhang GL; Wang XM
J Cancer; 2021; 12(17):5164-5172. PubMed ID: 34335933
[No Abstract] [Full Text] [Related]
20. Albumin-Bound Paclitaxel: A Review in Non-Small Cell Lung Cancer.
Blair HA; Deeks ED
Drugs; 2015 Nov; 75(17):2017-24. PubMed ID: 26541764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]